-

05:14:57 AM

BHC Stock News

BHC - Bausch Health Companies Inc

06/06/23 8:00 AM

NYSE : BHC

Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration

LAVAL, QC / ACCESSWIRE / June 6, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, understand that in a June 2, 2023, letter, the U.S. Food and Drug Administration (FDA) granted Norwich Pharmaceuticals Inc. Tentative Approval of its

RHEA-AI

positive

05/31/23 8:00 AM

NYSE : BHC

OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease

Bausch Health Companies Inc. and its oral health care business, OraPharma, today announced its collaboration with World Series Champion, Alex Rodriguez, to launch a national awareness campaign about the prevalence and...

RHEA-AI

neutral

05/22/23 9:39 AM

Nasdaq : VLY, KBRA, BHC

KBRA Releases First-Quarter 2023 U.S. Bank Compendium

Bank Compendium, providing the latest view of the U.S. banking industry and analysis of 1 Q23 results for U.S. banks with KBRA long-term ratings. In this edition, we discuss the U.S. banking industry landscape in the aftermath of March events and our views on commercial real estate. The Compendium includes 1 Q23 summaries on all publicly traded U.S. banks in KBRA’ s...

RHEA-AI

neutral

05/18/23 8:00 AM

NYSE : BHC

clinical trial

New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis

Novel Trial to Study the Reduction of Certain Pathogens Following Scaling and Root Planing ProcedureLAVAL, QC / ACCESSWIRE / May 18, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its oral health care business, OraPharma, today announced the publication of a new study, which showed

RHEA-AI

neutral

05/17/23 1:20 PM

NYSE : BHC

fda approval

U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029

LAVAL, QC / ACCESSWIRE / May 17, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. District Court of Delaware in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc., has denied

RHEA-AI

neutral

05/17/23 8:00 AM

NYSE : BHC

Bausch Health Announces 2023 Annual Meeting of Shareholder Results

LAVAL, QC / ACCESSWIRE / May 17, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2023 annual meeting of shareholders (the "Annual Meeting").The 10 directors nominated at the Company's Annual Meeting held on May 16, 2023, were elected by a vote of

RHEA-AI

neutral

05/08/23 8:00 AM

NYSE : BHC

Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023

Five XIFAXAN® (rifaximin) and TRULANCE® (plecanatide) Research Posters Also to Be PresentedLAVAL, QC / ACCESSWIRE / May 8, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), the gastroenterology (GI)

RHEA-AI

negative

05/04/23 7:00 AM

NYSE : BHC

earnings

Bausch Health Announces First-Quarter 2023 Results

First-Quarter revenues of $1.94 billion, up 1% reported and 4% organic1Solid revenue growth across core products, led by Xifaxan with 7% reported growthMid- and late-stage product pipeline advancingBausch Health provides consolidated full-year guidance, and Bausch Health (excl. B+L) confirms 2023

RHEA-AI

negative

05/01/23 8:00 AM

NYSE : BHC

Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel

PDUFA Action Date is October 20, 2023LAVAL, QC / ACCESSWIRE / May 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for

RHEA-AI

neutral

04/24/23 8:00 AM

NYSE : BHC

partnership

Salix Partners with the Colorectal Cancer Alliance on Community Screening Program

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced a partnership with

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

BHC Data

IndustryPharmaceutical Preparation Manufacturing
Websitebauschhealth.com
CeoThomas J. Appio
Security nameBausch Health Companies Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees21100
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2150 St. ElzEar Boulevard West
StateQC
CityLaval
ZipH7L4A8
CountryCA
Phone5147446792

About Bausch Health Companies Inc

bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###